Guggenheim Maintains Buy on Veracyte, Raises Price Target to $65

Benzinga Newsdesk www.benzinga.com Positive 80.7%

Neg 0% Neu 0% Pos 80.7%

Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $45 to $65.

Comments

No comments yet. Be the first!